Jeffrey C. Goh

9.9k total citations
56 papers, 516 citations indexed

About

Jeffrey C. Goh is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Jeffrey C. Goh has authored 56 papers receiving a total of 516 indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 38 papers in Pulmonary and Respiratory Medicine and 13 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Jeffrey C. Goh's work include Cancer Immunotherapy and Biomarkers (24 papers), Prostate Cancer Treatment and Research (20 papers) and Renal cell carcinoma treatment (19 papers). Jeffrey C. Goh is often cited by papers focused on Cancer Immunotherapy and Biomarkers (24 papers), Prostate Cancer Treatment and Research (20 papers) and Renal cell carcinoma treatment (19 papers). Jeffrey C. Goh collaborates with scholars based in Australia, United States and Spain. Jeffrey C. Goh's co-authors include Emmanuel S. Antonarakis, Johann S. de Bono, Haiyan Wu, Christian Poehlein, Christopher Hoimes, Kristiina Ojamaa, Linda Mileshkin, Charles G. Drake, Camillo Porta and Robert J. Motzer and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Gynecologic Oncology.

In The Last Decade

Jeffrey C. Goh

51 papers receiving 507 citations

Peers

Countries citing papers authored by Jeffrey C. Goh

Since Specialization

Citations

This map shows the geographic impact of Jeffrey C. Goh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey C. Goh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey C. Goh more than expected).

Fields of papers citing papers by Jeffrey C. Goh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey C. Goh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey C. Goh. The network helps show where Jeffrey C. Goh may publish in the future.

Co-authorship network of co-authors of Jeffrey C. Goh

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey C. Goh. A scholar is included among the top collaborators of Jeffrey C. Goh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey C. Goh. Jeffrey C. Goh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer 2025 ·European Urology Oncology ·Niven Mehra, Emmanuel S. Antonarakis, Se Hoon Park, Jeffrey C. Goh, Ray McDermott, (unknown), Peter C.C. Fong, Richard Greil, Maria De Santis, Patricio Yañez, Eric Yi‐Hsiu Huang, Stephen Begbie, Felipe Rey, Gero Kramer, Hiroyoshi Suzuki, (unknown), Sameer R. Ghate, Yi Cui, Christian Hosius, Evan Y. Yu	1
2	BRCA Mutation Testing in Men With Metastatic Castration‐Resistant Prostate Cancer: Practical Guidance for Australian Clinical Practice 2025 ·Asia-Pacific Journal of Clinical Oncology ·Arun Azad, Howard Gurney, (unknown), Jeffrey C. Goh, Vivek Rathi	0
3	Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma 2025 ·International Journal of Gynecological Cancer ·Andreas Obermair, Val Gebski, Jeffrey C. Goh, (unknown), (unknown), (unknown), Orla McNally, Eva Baxter, Thomas W. Jobling, Linda Mileshkin	0
4	Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study 2025 ·Annals of Oncology ·Christian Gratzke, Mustafa Özgüroğlu, (unknown), Mehmet Alı Nahıt Şendur, Margitta Retz, Jeffrey C. Goh, Wolfgang Loidl, Gautam Jayram, Seok‐Soo Byun, Cheol Kwak, Mariusz Kwiatkowski, Ray Manneh Kopp, Juan Carlos Vázquez Limón, (unknown), Ugo De Giorgi, Karine Martins da Trindade, Chen Niu, Yang Liu, Christian Poehlein, Josep M. Piulats	1
5	The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Primary Staging of Selected Renal Tumours: Initial Experience in a Multicentre Cohort 2024 ·European Urology Focus ·(unknown), (unknown), Handoo Rhee, (unknown), Sheliyan Raveenthiran, Anita Pelecanos, (unknown), Jeffrey C. Goh, (unknown), Rhiannon McBean, (unknown), Steven N. Goodman, Nigel Dunglison, Rachel Esler, Anojan Navaratnam, John Yaxley, Paul Thomas, David A. Pattison, Matthew J. Roberts	4
6	716MO Efficacy and safety of sacituzumab tirumotecan (sac-TMT) plus pembrolizumab in patients with recurrent or metastatic cervical cancer 2024 ·Annals of Oncology ·Jing Wang, (unknown), Yi Huang, (unknown), Jeffrey C. Goh, Kui Jiang, Gongqi Yu, Liangan Chen, Diane Provencher, Yiyun Tang, Shuxiang Guo, (unknown), (unknown), Elliot Chartash, Yi Zhou, Xing Jin, Junbo Ge, Xiaojiang Wu	4
7	Pre-post feasibility trial of a telephone-delivered exercise intervention for patients during chemotherapy for recurrent ovarian cancer: the ECHO-R trial protocol 2024 ·BMJ Open ·Sandra C. Hayes, Rosalind R. Spence, Monika Janda, Elizabeth Eakin, Catherine Shannon, Jeffrey C. Goh, Vanessa L. Beesley, Dimitrios Vagenas, Penelope M. Webb, Jermaine Coward, Louisa G. Gordon, (unknown), (unknown), Sheree Rye, (unknown), (unknown), Marcelo Nascimento, James Nicklin, (unknown), Andreas Obermair	0
8	1886P Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601) 2023 ·Annals of Oncology ·Craig Gedye, Carole A. Harris, Martin R. Stockler, (unknown), (unknown), Jeffrey C. Goh, Andrew Martin, Craig Underhill, David Pook, Laurence E. Krieger, Ganessan Kichenadasse, Abhishek Joshi, Shalini Subramaniam, (unknown), (unknown), Anthony M. Joshua, Guy C. Toner, P. Vasey, Prashanth Prithviraj, Ian D. Davis	0
9	LBA84 Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901) 2023 ·Annals of Oncology ·Louise Emmett, Shalini Subramaniam, Megan Crumbaker, Anthony M. Joshua, Andrew Weickhardt, (unknown), Siobhan Ng, Roslyn J. Francis, Jeffrey C. Goh, David A. Pattison, (unknown), Ian Kirkwood, Shahneen Sandhu, Amy Nguyen, Craig Gedye, Natalie Rutherford, Michael S. Hofman, Andrew Martin, Martin R. Stockler, Ian D. Davis	7
10	Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management 2023 ·European Journal of Nuclear Medicine and Molecular Imaging ·(unknown), (unknown), (unknown), Handoo Rhee, (unknown), Sheliyan Raveenthiran, (unknown), Rhiannon McBean, (unknown), Steven N. Goodman, Nattakorn Dhiantravan, Rachel Esler, Nigel Dunglison, Anojan Navaratnam, John Yaxley, Paul Thomas, David A. Pattison, Jeffrey C. Goh, (unknown), Matthew J. Roberts	4
11	Evolution: Phase II study of radionuclide ¹⁷⁷Lu-PSMA-617 therapy versus ¹⁷⁷Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001). 2023 ·Journal of Clinical Oncology ·Shahneen Sandhu, Shalini Subramaniam, Michael S. Hofman, Martin R. Stockler, Andrew Martin, Izabella Pokorski, Jeffrey C. Goh, David A. Pattison, Nattakorn Dhiantravan, Craig Gedye, Natalie Rutherford, Anthony M. Joshua, Thean Hsiang Tan, Ian Kirkwood, Sze Ting Lee, Andrew Weickhardt, Ramin Alipour, Andrew Nguyen, Ian D. Davis, Louise Emmett, (unknown)	17
12	Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). 2023 ·Journal of Clinical Oncology ·Robert J. Motzer, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, B. Yа. Alekseev, Sun Young Rha, Jaime R. Merchan, Jeffrey C. Goh, Anil Kapoor, Ugo De Giorgi, Bohuslav Melichar, Sung‐Hoo Hong, Howard Gurney, (unknown), Cixin He, Chinyere E. Okpara, Jodi A. McKenzie, Toni K. Choueiri	25
13	2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma 2022 ·International Journal of Gynecological Cancer ·Robert L. Coleman, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I. Weberpals, Andrew R. Clamp, Giovanni Scambia, Alexandra Léary, Robert W. Holloway, Margarita Amenedo, Peter C.C. Fong, Jeffrey C. Goh, David M. O’Malley, Sandra Goble, Lara Maloney, Jonathan A. Ledermann	16
14	Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study 2022 ·Cancer Urology ·Robert J. Motzer, Camillo Porta, B. Yа. Alekseev, Sun Young Rha, Toni K. Choueiri, María José Méndez-Vidal, Sung‐Hoo Hong, Anil Kapoor, Jeffrey C. Goh, Masatoshi Eto, L. Michelle Bennett, (unknown), (unknown), (unknown), Rodolfo F. Perini, Cixin He, Kalgi Mody, David Cella	1
15	TheraP: ¹⁷⁷Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603). 2022 ·Journal of Clinical Oncology ·Michael S. Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony M. Joshua, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Roslyn J. Francis, Craig Gedye, Natalie Rutherford, Alison Yan Zhang, Margaret McJannett, Martin R. Stockler, Scott Williams, Andrew Martin, Ian D. Davis, (unknown)	35
16	611P Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study 2021 ·Annals of Oncology ·Emmanuel S. Antonarakis, Josep M. Piulats, Marine Gross‐Goupil, Jeffrey C. Goh, Ulka N. Vaishampayan, Ronald de Wit, Tuomo Alanko, Satoshi Fukasawa, Ken‐ichi Tabata, (unknown), Raanan Berger, Kristiina Ojamaa, Christopher Hoimes, Ahmet Sezer, Aurelius Omlin, Jeffrey Yachnin, Chen Niu, Christian Poehlein, Charles Schloss, Johann S. de Bono	7
17	821P Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study 2020 ·Annals of Oncology ·Andrew Dean, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Nicoletta Colombo, (unknown), Andrew R. Clamp, Giovanni Scambia, Alexandra Léary, Robert W. Holloway, Margarita Amenedo, Peter C.C. Fong, Jeffrey C. Goh, David M. O’Malley, T. Cameron, Lara Maloney, Sandra Goble, Robert L. Coleman, Jonathan A. Ledermann	1
18	231P Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) 1-3 from KEYNOTE-199 2020 ·Annals of Oncology ·Jeffrey C. Goh, Josep M. Piulats, Marine Gross‐Goupil, Ulka N. Vaishampayan, Ronald de Wit, Tuomo Alanko, Satoshi Fukasawa, Ken‐ichi Tabata, (unknown), Raanan Berger, Haiyan Wu, (unknown), Charles Schloss, Johann S. de Bono, Emmanuel S. Antonarakis	2
19	Update on KEYNOTE-199, cohorts 1-3: Pembrolizumab (pembro) for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC). 2020 ·Journal of Clinical Oncology ·Emmanuel S. Antonarakis, Josep M. Piulats, Marine Gross‐Goupil, Jeffrey C. Goh, Ulka N. Vaishampayan, Ronald de Wit, Tuomo Alanko, Satoshi Fukasawa, Ken‐ichi Tabata, Susan Feyerabend, Raanan Berger, (unknown), Jeri Kim, Charles Schloss, Johann S. de Bono	4
20	Evaluation of rucaparib in platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts) with or without residual bulky disease at baseline in the ARIEL3 study. 2018 ·Journal of Clinical Oncology ·Carol Aghajanian, Robert L. Coleman, Amit M. Oza, Domenica Lorusso, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I. Weberpals, Andrew R. Clamp, Giovanni Scambia, Alexandra Léary, Robert W. Holloway, Peter C.C. Fong, Jeffrey C. Goh, David M. O’Malley, Susana Banerjee, Kenton Wride, (unknown), Jonathan A. Ledermann	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact